Written by : Dr. Aishwarya Sarthe
January 23, 2025
The investment will enable Exsure to complete its non-clinical studies and present the data to the CDSCO by the end of the year.
Unicorn India Ventures, a prominent venture capitalist firm, has pledged INR 3 Cr in funding for Bhubaneswar-based biotech startup Exsure.
The investment will enable Exsure to complete its non-clinical studies and present data to the Central Drugs Standard Control Organization (CDSCO) by the end of the year.
Exsure, founded in 2021, is developing a patented exosomal drug-delivery platform to reduce the toxicity and side effects of anti-cancer drugs.
Over the past year, the startup has been conducting non-clinical studies in collaboration with a contract research organization (CRO) and recently met one of its preclinical objectives.
Exsure's exosomal drug-delivery platform targets both cancer cells and cancer stem cells, aiming to address significant gaps in oncology treatment. The startup seeks to minimize the adverse effects often associated with anti-cancer therapies, providing a potentially safer alternative for patients.
Bhaskar Majumdar, Managing Partner at Unicorn India Ventures, said, “The funding accelerates Exsure’s mission to deploy solutions at a global level. We believe Exsure will sustain its momentum and achieve significant growth due to its potential for transformative breakthroughs through its nano delivery platform.”
Exsure is strategically positioned within the rapidly growing Indian biotech sector, projected to reach $150 billion by the end of 2025 and expand further to $270–$300 billion by 2030. The startup plans to use the recent funding to enhance its team and strengthen its global marketing and sales efforts.